Dynavax Technologies

Expanding US Adult Immunization Markets Will Unlock Future Opportunities

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

14 Sep 24

Updated

04 Dec 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-15.3%

7D

-4.2%

Loading

1Y

-15.3%

7D

-4.2%

You can edit this narrative until Dec 5 4:05 PM. Then, changes will post as Updates.

Author's Valuation

US$19.2543.4% undervalued

AnalystConsensusTarget Fair Value

Shared on 04 Dec 25

Fair value Decreased 12%

DVAX: Share Buybacks Will Drive Future Upside Despite Lowered Market Multiple

Analysts have trimmed their price target on Dynavax Technologies from 21.80 dollars to 19.25 dollars, reflecting slightly higher discount rate assumptions and a more conservative view on future valuation multiples, despite largely unchanged long term growth and margin expectations. What's in the News Board of Directors authorized a new share repurchase plan in October 2025, enabling the company to buy back common stock.

Shared on 20 Nov 25

Fair value Decreased 4.39%

DVAX: Share Repurchase And Positive Trial Data Will Drive Further Upside

Analysts have revised their price target for Dynavax Technologies downward from $22.80 to $21.80. They cite slight adjustments to key financial assumptions, including discount rate, revenue growth, and profit margin forecasts.

Shared on 01 May 25

Fair value Decreased 2.04%

Shared on 23 Apr 25

Fair value Decreased 12%

Shared on 17 Apr 25

Fair value Decreased 2.00%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 9.80%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 11 Mar 25

Fair value Increased 5.65%

AnalystConsensusTarget has decreased revenue growth from 19.5% to 17.3%, increased profit margin from 21.2% to 25.3% and decreased future PE multiple from 45.7x to 27.7x.

AnalystConsensusTarget Fair Value

US$19.25

43.4% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

13.31%

Biotech revenue growth rate

9.24%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.41%

Calculation

US$131.88m

Earnings '28

x

17.91x

PE Ratio '28

=

US$2.36b

Market Cap '28

US$2.36b

Market Cap '28

/

99.55m

No. shares '28

=

US$23.72

Share Price '28

US$23.72 Share Price '28

Discounted to 2025 @ 7.41% p.a.

=

US$19.14

Fair Value '25